BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND TCL1A, P56279, 8115, ENSG00000100721, TCL1 AND Treatment
17 results:

  • 1. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
    Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
    Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature.
    Gjelberg HK; Helgeland L; Liseth K; Micci F; Sandnes M; Russnes HG; Reikvam H
    Curr Oncol; 2023 Nov; 30(11):10007-10018. PubMed ID: 37999147
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm.
    He J; Garcia MB; Connors JS; Nuñez CA; Quesada AE; Gibson A; Roth M; Cuglievan B; Pemmaraju N; McCall D
    J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1001-e1004. PubMed ID: 37661300
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jain A; Sweet K
    J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [Blastic plasmacytoid dendritic cell neoplasm: A clinico-pathological retrospective analysis of thirteen cases].
    Nong L; Wang W; Liang L; Li D; Li X; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):308-314. PubMed ID: 37042142
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review.
    Wang Y; Xiao L; Yin L; Zhou L; Deng Y; Deng H
    Medicine (Baltimore); 2023 Feb; 102(7):e32904. PubMed ID: 36800625
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. From the archives of MD Anderson cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature.
    Nahmod KA; Thakral B; Aakash FNU; Iyer SP; Medeiros LJ; Quesada AE
    Ann Diagn Pathol; 2023 Feb; 62():152077. PubMed ID: 36549077
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
    Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
    Zhang X; Sun J; Yang M; Wang L; Jin J
    Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Genetic Underpinnings of Musculoskeletal Pain During treatment With Aromatase Inhibitors for Breast cancer: A Biological Pathway Analysis.
    Zhu Y; Koleck TA; Bender CM; Conley YP
    Biol Res Nurs; 2020 Apr; 22(2):263-276. PubMed ID: 31847542
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
    Gutjahr JC; Szenes E; Tschech L; Asslaber D; Schlederer M; Roos S; Yu X; Girbl T; Sternberg C; Egle A; Aberger F; Alon R; Kenner L; Greil R; Orian-Rousseau V; Hartmann TN
    Blood; 2018 Mar; 131(12):1337-1349. PubMed ID: 29352038
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.
    Hanna BS; Öztürk S; Seiffert M
    Mol Immunol; 2019 Jun; 110():77-87. PubMed ID: 29173971
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches.
    Pagano L; Valentini CG; Grammatico S; Pulsoni A
    Br J Haematol; 2016 Jul; 174(2):188-202. PubMed ID: 27264021
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-tcl1 mouse model.
    Blunt MD; Carter MJ; Larrayoz M; Smith LD; Aguilar-Hernandez M; Cox KL; Tipton T; Reynolds M; Murphy S; Lemm E; Dias S; Duncombe A; Strefford JC; Johnson PW; Forconi F; Stevenson FK; Packham G; Cragg MS; Steele AJ
    Blood; 2015 Jun; 125(26):4032-41. PubMed ID: 25957390
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Blastic plasmacytoid dendritic cell neoplasm revealed by ecchymotic lesions on the face].
    Ahogo KC; Wantz M; Cliquennois M; Gosset P; Lebas D; Modiano P
    Ann Dermatol Venereol; 2014 Jan; 141(1):43-7. PubMed ID: 24461094
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Modifying akt signaling in B-cell chronic lymphocytic leukemia cells.
    Hofbauer SW; Piñón JD; Brachtl G; Haginger L; Wang W; Jöhrer K; Tinhofer I; Hartmann TN; Greil R
    Cancer Res; 2010 Sep; 70(18):7336-44. PubMed ID: 20823161
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.